Abiopharma

🔍 Bizily Scott (Executive)

Company: 4D Molecular Therapeutics, Inc. (FDMT)

Report Date: 2026-08-13

Detailed Transactions and Holdings:

• Acquired 1,635 shares of Common Stock at $4.14 per share (Direct)
  Date: 2026-08-13 | Code: M | equity_swap_involved: false | shares_owned_after: 10,252.00 | transaction_form_type: 4
• Sold 1,635 shares of Common Stock at $12.0 per share (Direct)
  Date: 2026-08-13 | Code: S | equity_swap_involved: false | shares_owned_after: 8,617.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 1,635 shares of Common Stock at $4.14 per share (Direct)
  Date: 2026-08-17 | Code: M | equity_swap_involved: false | shares_owned_after: 10,252.00 | transaction_form_type: 4
• Sold 1,635 shares of Common Stock at $12.2 per share (Direct)
  Date: 2026-08-17 | Code: S | equity_swap_involved: false | shares_owned_after: 8,617.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,635 shares of Stock Option (Right to Buy) at $4.14 per share (Derivative)
  Date: 2026-08-13 | Code: M | Expires: 2035-03-05 | equity_swap_involved: false | shares_owned_after: 61,336.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 1,635 shares of Stock Option (Right to Buy) at $4.14 per share (Derivative)
  Date: 2026-08-17 | Code: M | Expires: 2035-03-05 | equity_swap_involved: false | shares_owned_after: 59,701.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026.
• F2: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.